Endo International plc – (NASDAQ:ENDP) (TSE:ENL) shares dropped 9.8% on Tuesday . The stock traded as low as $5.95 and last traded at $6.05. Approximately 10,815,992 shares were traded during trading, an increase of 79% from the average daily volume of 6,044,161 shares. The stock had previously closed at $6.71.

ENDP has been the subject of several research analyst reports. JMP Securities downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Monday, February 26th. Leerink Swann initiated coverage on Endo International in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 target price for the company. Mizuho reaffirmed a “buy” rating and set a $12.00 target price (down from $14.00) on shares of Endo International in a research note on Wednesday, January 3rd. Canaccord Genuity set a $7.00 target price on Endo International and gave the stock a “hold” rating in a research note on Wednesday, February 21st. Finally, Vetr downgraded Endo International from a “strong-buy” rating to a “buy” rating and set a $8.92 price objective for the company. in a research note on Monday, December 18th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Endo International presently has an average rating of “Hold” and a consensus target price of $9.68.

How to Become a New Pot Stock Millionaire

The company has a current ratio of 1.02, a quick ratio of 0.85 and a debt-to-equity ratio of 17.00. The company has a market cap of $1,351.21, a price-to-earnings ratio of 1.58 and a beta of 0.35.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.15. The company had revenue of $768.64 million during the quarter, compared to analysts’ expectations of $762.29 million. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The firm’s quarterly revenue was down 38.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.77 EPS. equities research analysts anticipate that Endo International plc – will post 2.32 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the business. Paloma Partners Management Co purchased a new stake in Endo International in the 4th quarter valued at $122,000. Oakbrook Investments LLC purchased a new stake in Endo International in the 4th quarter valued at $133,000. LMR Partners LLP purchased a new stake in Endo International in the 3rd quarter valued at $148,000. Xact Kapitalforvaltning AB purchased a new stake in Endo International in the 4th quarter valued at $157,000. Finally, Elkfork Partners LLC purchased a new position in shares of Endo International during the 4th quarter worth $194,000. Institutional investors own 94.72% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/endo-international-endp-trading-down-9-8/1957149.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.